Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Halozyme Therapeutics reported a strong first quarter of 2022, with revenue of $117.3 million, marking a 32% year-over-year increase. GAAP diluted earnings per share rose to $0.43 while non-GAAP diluted EPS reached $0.47. Record quarterly royalties hit $69.6 million, an 89% growth compared to the prior year. The company reiterated its full-year 2022 revenue guidance of $530 million to $560 million, forecasting 20-26% growth and a GAAP operating income of $350 million to $380 million.
Halozyme Therapeutics (NASDAQ: HALO) announces a Q1 2022 Conference Call on May 10 at 4:30 p.m. ET. Dr. Helen Torley will lead the discussion. Financial results for the quarter ending March 31, 2022 will be released following market close on the same date. Interested parties can register for the call via the provided link and access the live webcast through the Investors section of Halozyme's website. The company highlights its innovative ENHANZE® technology, which improves drug delivery, benefiting over 600,000 patients globally.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has initiated a cash tender offer to acquire all outstanding common shares of Antares Pharma, Inc. (NASDAQ: ATRS) for $5.60 per share. The offer follows the Merger Agreement dated April 12, 2022, and is set to expire on May 23, 2022, unless extended. Conditions for closing include the tender of a majority of Antares shares and compliance with regulatory approvals. Antares' Board of Directors recommends stockholders accept the offer. The transaction aims to enhance Halozyme's position in the biopharmaceutical market.
Halozyme Therapeutics is set to acquire Antares Pharma for $5.60 per share, valuing the transaction at approximately $960 million. This acquisition aims to enhance Halozyme's drug delivery business and diversify its revenue streams through Antares' auto injector platform. The deal is anticipated to be immediately accretive to Halozyme's revenue and non-GAAP earnings in 2022, with significant growth projections into 2027. The merger is backed by both companies' boards and expected to close in the first half of 2022.
Halozyme Therapeutics (NASDAQ: HALO) announced a global collaboration with Chugai Pharmaceutical for the use of its ENHANZE® drug delivery technology. Chugai will pay an upfront fee of $25 million and potential future payments totaling up to $160 million based on specific milestones. This agreement marks Halozyme's twelfth collaboration involving over 60 therapeutic targets and aims to enhance patient treatment options through subcutaneous injections. Halozyme will also benefit from royalties on sales of products utilizing this technology.
The recent Phase 3 ADAPT-SC study results demonstrate that subcutaneously administered efgartigimod shows noninferior total IgG reduction at day 29 compared to intravenous administration, a significant milestone for Halozyme (NASDAQ: HALO). This achievement positions the treatment for generalized myasthenia gravis (gMG) favorably, paving the way for argenx to submit a Biologics License Application (BLA) to the FDA by the end of 2022. The success underscores the effectiveness of Halozyme's ENHANZE® technology in enhancing drug delivery options.
Halozyme Therapeutics (NASDAQ: HALO) has appointed Moni Miyashita to its board of directors, bringing over 25 years of experience in corporate strategy, mergers & acquisitions, and business transformation. The CEO, Dr. Helen Torley, expressed excitement over Miyashita's expertise, which aligns with the company's goal to expand growth opportunities. Miyashita, previously with Valo Health and IBM, aims to leverage her experience to enhance Halozyme's strategic initiatives. Halozyme is recognized for its ENHANZE® technology, improving treatment experiences for patients globally.
Halozyme Therapeutics reported robust financial results for Q4 and full year 2021, with total revenue hitting $443.3 million, a 66% increase Year-over-Year (YoY). Royalty revenue soared 130% YoY, driven mainly by the subcutaneous products DARZALEX® and Phesgo®. The company anticipates a further 50% growth in royalty revenue in 2022. Although Q4 revenue dropped to $102.0 million from $121.7 million in 2020, net income for the full year totaled $402.7 million, or $2.74 per share. Halozyme's guidance for 2022 projects revenues of $530-560 million, with a net income of $270-295 million.
Halozyme Therapeutics (NASDAQ: HALO) has announced it will host a webcast for its fourth quarter 2021 financial results on February 22, 2022, at 4:30 p.m. ET. CEO Dr. Helen Torley will lead the call, following the release of financial results after market close. Halozyme emphasizes its innovative ENHANZE® technology, which has improved treatment times for over 500,000 patients globally across five products. The company partners with major biopharmaceutical companies, generating revenue through collaborations and royalties.
Halozyme Therapeutics (NASDAQ: HALO) has promoted Nicole LaBrosse to Chief Financial Officer (CFO), succeeding Elaine Sun, who is leaving for another opportunity. LaBrosse, with over 18 years of experience, joined Halozyme in 2015 and has held progressively responsible roles, including Vice President of Finance since 2020. CEO Helen Torley expressed confidence in LaBrosse's ability to support the company's growth. Halozyme aims to improve patient experiences through its ENHANZE® technology, which streamlines treatment delivery, impacting over 500,000 patients globally.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
